Teyro Labs: FDA regulatory profile

Teyro Labs appears in 1 indexed U.S. FDA record: 1 drug-shortage entry (from 4 openFDA source rows), naming 1 distinct product. Latest dated event: a shortage record dated 2026-08-18. Observations run 2023-04-28 to 2026-08-18 — 1208 days, 2 dated records across 2 calendar years, busiest 2026 with 1. Shortages: 1 current, averaging 4 package lines each across 1 FDA therapeutic category, 4 strengths, 17 package NDCs and 2 brand names. 2 related firms and 2 adjacent shortage entries are linked below, each by a shared shortage entry, substance or therapeutic category. Every figure here is a count or a date computed from the indexed FDA datasets over a finite window: coverage-limited activity signals, never quality ratings or judgements about the firm. By year: 2026 (1), 2023 (1). Shortage entries include Carboplatin Injection (Current, since 2023-04-28, 4 lines). FDA therapeutic categories covered: Oncology. Strengths reported: 150 mg/15 mL (10 mg/mL) Multiple Dose Vial, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial and 600 mg/60 mL (10 mg/mL) Multiple Dose Vial. This firm appears in 1 indexed record, which is below the threshold this site requires before treating a manufacturer page as a standalone regulatory profile (only 1 indexed record). The page is published so the record remains reachable and verifiable, and it links on to the underlying FDA records, but it is marked noindex and left out of the sitemap: a single appearance of a company name is not a regulatory history, and presenting it as one would overstate what the data supports. Should further records reference this firm in a later ingestion, the page becomes a full profile automatically.